


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-EE9BAF20-6430-4295-ABDF-2A090B99D2CE_4_en-US
DOI: https://doi.org/10.31003/USPNF_M4107_04_01
DOI Ref: z6cy0

© 2025 USPC
Do not distribute

Rufinamide



$C_{10}H_8F_2N_4O$ 238.19

1*H*-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-;

1-(2,6-Difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide CAS RN®: 106308-44-5; UNII: WFW942PR79.

DEFINITION

Rufinamide contains NLT 98.0% and NMT 102.0% of $C_{10}H_8F_2N_4O$, calculated on the as-is basis.

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy: 197K* ▲ (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Use amber glassware for all volumetric solutions.

Diluent: Methanol and tetrahydrofuran (50:50)

Mobile phase: Methanol, tetrahydrofuran, and water (12:5:83)

System suitability stock solution: 0.8 mg/mL of [USP Rufinamide RS](#) and 4 µg/mL each of [USP Rufinamide Related Compound A RS](#) and [USP Rufinamide Related Compound B RS](#) in *Diluent*. [NOTE—[USP Rufinamide Related Compound B RS](#) is used for peak identification purposes only.]

System suitability solution: 0.2 mg/mL of [USP Rufinamide RS](#) and 0.8 µg/mL each of [USP Rufinamide Related Compound A RS](#) and [USP Rufinamide Related Compound B RS](#) in water from the *System suitability stock solution*

Standard stock solution: 0.8 mg/mL of [USP Rufinamide RS](#) in *Diluent*

Standard solution: 0.2 mg/mL of [USP Rufinamide RS](#) in water from the *Standard stock solution*

Sample stock solution: 0.8 mg/mL of Rufinamide in *Diluent*

Sample solution: 0.2 mg/mL of Rufinamide in water from the *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 12.5-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: 2.6 times the retention time of the rufinamide peak

System suitability

[NOTE—For relative retention times refer to [Table 1](#) in *Organic Impurities*.]

Sample: *System suitability solution*

Suitability requirements

Tailing factor: NMT 1.2 for rufinamide

Resolution: NLT 2.5 between rufinamide and rufinamide related compound A

Relative standard deviation: NMT 1.0% for rufinamide and NMT 5.0% for rufinamide related compound A

Analysis**Samples:** *Standard solution* and *Sample solution*Calculate the percentage of rufinamide ($C_{10}H_8F_2N_4O$) in the portion of the sample taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Rufinamide RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Rufinamide in the *Sample solution* (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the as-is basis**IMPURITIES**• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%• **ORGANIC IMPURITIES**

Use amber glassware for all volumetric solutions.

Diluent, Mobile phase, System suitability stock solution, System suitability solution, Standard stock solution, Sample stock solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.**Standard solution:** 0.8 µg/mL of [USP Rufinamide RS](#) in water from the *Standard stock solution***Analysis****Samples:** *Sample solution* and *Standard solution*

Calculate the percentage of any individual impurity in the portion of Rufinamide taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of each individual impurity from the *Sample solution* r_S = peak response of rufinamide from the *Standard solution* C_S = concentration of [USP Rufinamide RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Rufinamide in the *Sample solution* (mg/mL)**Acceptance criteria:** See [Table 1](#).**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Rufinamide	1.0	—
Rufinamide related compound A ^a	1.2	0.30
Rufinamide related compound B ^b	1.9	0.10
Any other individual impurity	—	0.05
Total impurities	—	0.50

^a 1-(2-Fluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide.^b Methyl 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxylate.**ADDITIONAL REQUIREMENTS**• **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.

- [USP REFERENCE STANDARDS \(11\)](#).
[USP Rufinamide RS](#)
[USP Rufinamide Related Compound A RS](#)
1-(2-Fluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide.
C₁₀H₉FN₄O 220.20
[USP Rufinamide Related Compound B RS](#)
Methyl 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxylate.
C₁₁H₉F₂N₃O₂ 253.20

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
RUFINAMIDE	Documentary Standards Support	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 50(5)

Current DocID: GUID-EE9BAF20-6430-4295-ABDF-2A090B99D2CE_4_en-US

DOI: https://doi.org/10.31003/USPNF_M4107_04_01

DOI ref: [z6cy0](#)

OFFICIAL